Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy

Blood (2024) 144 (Supplement 1): 4801.

https://doi.org/10.1182/blood-2024-209465

Published: 2024

Journal Articles

FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma

John Reiser, Szeman Ruby Chan, Ketan Mathavan, David Sillitti, Cristina Mottershead, Bethany Mattson, Melissandre Pache, Alma Gutierrez, Whitney Scoon, Yanni Zhu, Andrew Gilder, Christine Chen, Kimberly Staquet, Michael Ports, Charles Drake, Joseph Erhardt, Ryan Bjordahl, Jode P. Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 4560–4561.

https://doi.org/10.1182/blood-2022-170501

Published: 2022

Journal Articles

Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape

Bi-Huei Yang, Yu-Sheng Eason Lin, Soheila Shirinbak, Wen-I Yeh, Mochtar Pribadi, Hui-Yi Chu, Alma Gutierrez, Amit Mehta, Earl Avramis, Roseanna Petrovic, Benjamin Whitlock, Jason ORourke, Sjoukje van der Stegen, Tom Lee, Alec Witty, Eigen Peralta, Martin Hosking, Chia-Wei Chang, Bahram Valamehr

Blood (2021) 138 (Supplement 1): 2793.

https://doi.org/10.1182/blood-2021-153268

Published: 2021

Journal Articles

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2021-152985

Published: 2021

Journal Articles

Generation of Multiplexed Engineered, Off-the-Shelf CAR T Cells Uniformly Carrying Multiple Anti-Tumor Modalities to Prevent Tumor Relapse

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-138930

Published: 2020

Journal Articles

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Blood (2019) 134 (Supplement_1): 4434.

https://doi.org/10.1182/blood-2019-130584

Published: 2019

NARROW

Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy

FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma

Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy

Generation of Multiplexed Engineered, Off-the-Shelf CAR T Cells Uniformly Carrying Multiple Anti-Tumor Modalities to Prevent Tumor Relapse

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy

FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma

Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy

Generation of Multiplexed Engineered, Off-the-Shelf CAR T Cells Uniformly Carrying Multiple Anti-Tumor Modalities to Prevent Tumor Relapse

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only